Empreendimentos Pague Menos S.A. (BVMF:PGMN3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 2.48B +11.0% |
| Revenue (ttm) | 15.64B +14.3% |
| Net Income | 328.41M +102.0% |
| EPS | 0.49 +90.0% |
| Shares Out | 720.15M |
| PE Ratio | 7.04 |
| Forward PE | 5.64 |
| Dividend | 0.26 (7.47%) |
| Ex-Dividend Date | Dec 26, 2025 |
| Volume | 6,959,700 |
| Open | 3.500 |
| Previous Close | 3.470 |
| Day's Range | 3.400 - 3.590 |
| 52-Week Range | 3.090 - 7.620 |
| Beta | 0.03 |
| Analysts | Buy |
| Price Target | 6.78 (+96.52%) |
| Est. Earnings | Oct 30, 2026 |
About BVMF:PGMN3
Empreendimentos Pague Menos S.A. engages in the retail sale of medicines, perfumeries, and personal hygiene and beauty products in Brazil. The company offers medicines and health care products; personal hygiene products, including deodorant, intimate care, and oral hygiene; foot, hair, face, and hand care products; dermo and beauty products; and repellent, diaper, cloth, and food products, as well as other accessories for moms and babies. The company also offers vaccines, clinical analysis tests, and basic health services; clothing and accessor... [Read more]
Financial Performance
In 2025, BVMF:PGMN3's revenue was 14.91 billion, an increase of 17.91% compared to the previous year's 12.64 billion. Earnings were 260.28 million, an increase of 152.46%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PGMN3 stock is "Buy." The 12-month stock price target is R$6.78, which is an increase of 96.52% from the latest price.
News
Empreendimentos Pague Menos Earnings Call Transcript: Q2 2026
Record Q2 profitability and cash generation were driven by strong same-store sales, disciplined expense control, and market share gains, despite digital channel issues impacting GLP-1 sales. Continued deleveraging, robust investments in technology, and assertive store openings support a positive outlook.
Empreendimentos Pague Menos Earnings release: Q2 2026
Empreendimentos Pague Menos released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Empreendimentos Pague Menos Slides: Q2 2026
Empreendimentos Pague Menos has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Empreendimentos Pague Menos Document: Q2 2026
Empreendimentos Pague Menos filed a regulatory document on August 4, 2026 disclosing important business information.
Empreendimentos Pague Menos Earnings Call Transcript: Q1 2026
Q1 2026 saw 14.4% revenue growth, 36% EBITDA growth, and net income quadrupling year-over-year, with strong market share gains in the North and Northeast and a focus on continuous care customers. Margin expansion, disciplined capital allocation, and digital growth underpin a positive outlook.
Empreendimentos Pague Menos Earnings release: Q1 2026
Empreendimentos Pague Menos released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Empreendimentos Pague Menos Slides: Q1 2026
Empreendimentos Pague Menos has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Empreendimentos Pague Menos Document: Q1 2026
Empreendimentos Pague Menos filed a regulatory document on May 5, 2026 disclosing important business information.
Empreendimentos Pague Menos Earnings Call Transcript: Q4 2025
Achieved record revenue and EBITDA growth in 2025, driven by strong same-store sales, digital expansion, and operational efficiency. Market share and profitability improved, with disciplined capital allocation and a focus on scaling logistics and generics in 2026.
Empreendimentos Pague Menos Earnings release: Q4 2025
Empreendimentos Pague Menos released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.
Empreendimentos Pague Menos Slides: Q4 2025
Empreendimentos Pague Menos has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 2, 2026.
Empreendimentos Pague Menos Earnings Call Transcript: Q3 2025
Revenue grew 18% year-over-year, with same-store sales up 17.6% and EBITDA rising 36.4%. Prescription and generic drugs drove growth, while net income increased 50%. Market share, customer base, and store productivity all improved, with further gains expected.
Empreendimentos Pague Menos Earnings release: Q3 2025
Empreendimentos Pague Menos released its Q3 2025 earnings on November 4, 2025, summarizing the period's financial results.
Empreendimentos Pague Menos Slides: Q3 2025
Empreendimentos Pague Menos has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.
Empreendimentos Pague Menos Document: Q3 2025
Empreendimentos Pague Menos filed a regulatory document on November 4, 2025 disclosing important business information.